Case Report of a Novel Amino Acid Deletion in Codon 67 and T69G Substitution in the Reverse Transcriptase of HIV-1

Lorenzi P. , Opravil M. , Hirschel B. , Chave J.P. , Furrel H.J. , Sax H. , Perneger T. V. , Perrin L. , Kaiser L. , Yerly S. , & the Swiss HIV Cohort Study. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13: F17–F21.

Rodriguez Rosado R. , Briones C. , & Soriano V. Introduction of HIV drug-resistance testing in clinical practice. AIDS 1999; 13: 1007–1014.

Durant J. , Clevenbergh P. , Halfon P. , Delgiudice P. , Porsin S. , Simonet P. , Montagne N. , Boucher C.A. , Schapiro J.M. , & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199.

Baxter J.D. , Mayers D.L. , Wentworth D.N. , Neaton J.D. , & Merigan T.C. A pilot study of the short-term effects of anti-retroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, February 1999. Abstract LB8.

Vandamme A.M. , Van Laethem K. , & De Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999; 57: 337–361.

Imamichi T. , Sinha T. , Imamichi H. , Zhang Y.M. , Metcalf J. , Falloon J. , & Lane H.C. High-level resistance to 3′-azido-3'deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. Journal of Virology 2000; 74: 1023–1028.

HIV Sequence Database. Los Alamos National Laboratory. (http//hiv-web.lanl.gov/BASIC_BLAST/basic_blast.html and http://hiv-web.lanl.gov/TREETUTORIAL/tree-tutorial.html).

Kim E.Y. , Vrang L. , Oberg B. , & Merigan T.C. Anti-HIV-1 activity of 3′-fluoro-3′-deoxythymidine for different multidrug-resistant mutants. 6th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, February 2000. Abstract 742.